Teachers Retirement System of The State of Kentucky Acquires 249,357 Shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNA)

Teachers Retirement System of The State of Kentucky increased its position in shares of Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating) by 37.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 915,457 shares of the company’s stock after purchasing an additional 249,357 shares during the period. Teachers Retirement System of The State of Kentucky’s holdings in Ginkgo Bioworks were worth $3,689,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in DNA. Endurance Wealth Management Inc. raised its stake in shares of Ginkgo Bioworks by 100.0% during the 1st quarter. Endurance Wealth Management Inc. now owns 10,000 shares of the company’s stock worth $40,000 after acquiring an additional 5,000 shares in the last quarter. Financial Consulate Inc. purchased a new stake in shares of Ginkgo Bioworks in the 1st quarter valued at $40,000. Cambridge Investment Research Advisors Inc. purchased a new stake in shares of Ginkgo Bioworks in the 1st quarter valued at $43,000. B. Riley Wealth Management Inc. purchased a new stake in Ginkgo Bioworks during the first quarter worth $48,000. Finally, Hancock Whitney Corp purchased a new position in Ginkgo Bioworks during the first quarter valued at $48,000. 53.37% of the stock is owned by hedge funds and other institutional investors.

Ginkgo Bioworks Trading Down 4.5 %

NYSE DNA opened at $2.99 on Monday. The firm has a 50 day simple moving average of $2.97 and a 200-day simple moving average of $3.07. The company has a debt-to-equity ratio of 0.03, a quick ratio of 11.78 and a current ratio of 11.84. Ginkgo Bioworks Holdings, Inc. has a one year low of $2.09 and a one year high of $15.86. The firm has a market cap of $5.34 billion, a price-to-earnings ratio of -1.53 and a beta of 1.84.

Wall Street Analyst Weigh In

DNA has been the subject of several recent analyst reports. Jefferies Financial Group cut their price objective on shares of Ginkgo Bioworks from $11.50 to $4.35 in a research report on Thursday, June 16th. BTIG Research raised their price objective on shares of Ginkgo Bioworks from $5.00 to $6.00 and gave the stock a “buy” rating in a research report on Tuesday, August 16th. Finally, Raymond James raised their price objective on shares of Ginkgo Bioworks from $11.50 to $14.50 and gave the stock an “outperform” rating in a research report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $8.69.

Ginkgo Bioworks Profile

(Get Rating)

Ginkgo Bioworks Holdings, Inc, together with its subsidiaries, develops platform for cell programming. Its platform is used to program cells to enable biological production of products, such as novel therapeutics, food ingredients, and chemicals derived from petroleum. The company serves various end markets, including specialty chemicals, agriculture, food, consumer products, and pharmaceuticals.

Featured Articles

Want to see what other hedge funds are holding DNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ginkgo Bioworks Holdings, Inc. (NYSE:DNAGet Rating).

Institutional Ownership by Quarter for Ginkgo Bioworks (NYSE:DNA)

Receive News & Ratings for Ginkgo Bioworks Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ginkgo Bioworks and related companies with MarketBeat.com's FREE daily email newsletter.